Pfizer Seeks EUA for COVID-19 Vaccine in Children
The announcement was made by Pfizer and BioNTech on Twitter
Pfizer announced on Twitter that it and BioNTech have officially asked for an emergency use authorization (EUA) for its COVID-19 vaccine for children 5 to 11 years of age.
The companies announced positive topline results from the pivotal trial on Sept. 20, 2021, and they began submitting data from this trial to the FDA on Sept. 28.
In the trial, which included 2,268 participants 5 to less than 12 years of age, the vaccine demonstrated a favorable safety profile and elicited antibody responses using a two-dose regimen of 10 μg doses. These results were comparable to those recorded in a previous Pfizer-BioNTech study in people 16 to 25 years of age, who were immunized with 30 μg doses. The 10 μg dose was selected as the preferred dose for safety, tolerability and immunogenicity in children 5 to less than 12 years of age.
Related: Pfizer and BioNTech Submit Initial Data of COVID-19 Vaccine in Children
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
